“in 2025, we are expecting to get an additional 18 markets and four additional of our top 15 markets will launch this year.”

In context

“ming they're successful to follow, I think there's a lot of momentum behind ELREXFIO. And over the course of this year, we expect it to grow rapidly, driven primarily by increased demand in our top 100 accounts as well as increased adoption in the community setting, which I think positions ELREXFIO very, very well for the future as we expand indications into earlier lines of therapy in '26 and beyond. Albert Bourla: Thank you. And myself, I was quite impressed with community oncologist uptake of this product as quickly as it happened in the U.S. But also, we have very good news for ELREXFIO in international market. Alexandre? Alexandre de Germay: Yes, indeed ELREXFIO was commercially launched in already six markets in 2024, out of our top 15 markets, quite fast penetration. And of course, in 2025, we are expecting to get an additional 18 markets and four additional of our top 15 markets will launch this year. But the combination of the expand access plus the performance of the brands where we already have introduced the product gives us great confidence for accelerated growth. And to give you a sense, Japan is the second largest market outside of the U.S., and we had a significant and very rapid demand in Japan where ELREXFIO was introduced first to market, BCMA bispecific. And that's -- we've seen an immediate acceleration of utilization actually deep into the community in Japan. And where we've launched with other products, BCMA bispecific, like in the U.K., in Spain, in Italy, or markets where we have demonstrated ELREXFIO leadership, and we expect to continue this leadership position in 2025. So the combination of increased access and where we already introduced the growth expansions, ther”